Table 4.

Subgroup analyses for the primary outcomes in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure and the EMPEROR-Reduced trials

Subgroup	HR (95%CI) of dapagliflozin compared to placebo	HR (95%CI) of empagliflozin compared to placebo
Age
≤ 65 yr	0.78 (0.63–0.96)	0.71 (0.57–0.89)
> 65 yr	0.72 (0.60–0.85)	0.78 (0.66–0.93)
Sex
Male	0.73 (0.63–0.85)	0.80 (0.68–0.93)
Female	0.79 (0.59–1.06)	0.59 (0.44–0.80)
T2DM
Yes	0.75 (0.63–0.90)	0.72 (0.60–0.87)
No	0.73 (0.60–0.88)	0.78 (0.64–0.97)
eGFR < 60 mL/min/1.73 m2
Yes	0.72 (0.59–0.86)	0.83 (0.69–1.00)
No	0.76 (0.63–0.92)	0.67 (0.55–0.83)

T2DM: Type 2 diabetes mellitus; HR: Hazard ratio; CI: Confidence interval.